Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Heterologous prime/boost vaccination strategies are promising for inducing cytotoxic T-lymphocyte responses.
• Plasmid DNA primes are expensive and have shown disappointing immunogenicity in human trials.
• Novel priming immunogens are needed for effective heterologous immunization regimens.

Purpose of the Study:

• To explore novel priming immunogens for heterologous immunization regimens.
• To evaluate the immunogenicity of a recombinant Mycobacterium smegmatis strain expressing HIV-1 gp120.
• To assess the induction of antigen-specific memory CD8+ T cells.

Main Methods:

• Priming with a recombinant Mycobacterium smegmatis strain expressing HIV-1 gp120.
• Characterization of elicited CD4+ and CD8+ T lymphocytes.
• Boosting with a recombinant adenovirus expressing HIV-1 Env.
• Analysis of T-lymphocyte differentiation, memory cell markers (CD62L, CD27), and cytokine profiles.

Main Results:

• Priming with recombinant M. smegmatis elicited both CD4+ helper T cells and CD8+ T lymphocytes.
• The CD8+ T lymphocytes rapidly differentiated into memory cells.
• Recombinant-mycobacterium-induced T lymphocytes expanded robustly after boosting with recombinant adenovirus.
• Durable, antigen-specific memory CD8+ T cells were induced.

Conclusions:

• Recombinant Mycobacterium smegmatis is a viable and effective priming immunogen for inducing cellular immune responses.
• This approach offers a promising alternative to plasmid DNA primes in heterologous prime/boost vaccination strategies.
• The findings suggest potential for developing novel vaccines against HIV-1 and other pathogens.